TARGETED THERAPY FOR
LEUKEMIA (BCR-ABL)
Before targeted therapy, CML had a 3-5 year median survival. Today, most patients on BCR-ABL inhibitors have life expectancy approaching that of the general population. This is precision oncology at its most transformative.
BCR-ABL Inhibitor Options
| Drug | Generation | Key Features | Notes |
|---|---|---|---|
| Imatinib (Gleevec/Glivec) | First | Approved 2001; now generic; still clinically effective | Generic availability has dramatically reduced cost barrier globally |
| Dasatinib | Second | Faster, deeper molecular responses; CNS active | Pleural effusion risk; used in higher-risk patients and Ph+ ALL |
| Nilotinib | Second | Deep molecular responses; twice daily | Cardiovascular risk monitoring required |
| Bosutinib | Second | Alternative second-generation option | GI side effects; used in intolerant or resistant patients |
| Ponatinib | Third | Specifically designed for T315I resistance mutation | Significant cardiovascular risk; careful patient selection required |
| Asciminib (Scemblix) | Third (STAMP) | Different binding mechanism; active against T315I | Increasingly used in later-line settings; distinct mechanism from prior TKIs |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About BCR-ABL Targeted Therapy for Leukemia?
CancerFax connects patients with haematologic oncologists experienced in TKI management for CML and Ph+ ALL, including molecular monitoring and treatment-free remission assessment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.